Safety and efficacy of drospirenone used in a continuous combination with 17β-estradiol for prevention of postmenopausal osteoporosis

By Warming L.   Ravn P.   Nielsen T.   Christiansen C.  

Climacteric, Vol. 7, Iss. 1, 2004-01 ,pp. : 103-111

Informa Healthcare

Access to resources Recommend Favorite

One-year randomized study of the endometrial safety and bleeding pattern of 0.25 mg drospirenone/0.5 mg 17β-estradiol in postmenopausal women

By Genazzani A. R.  

Climacteric, Vol. 16, Iss. 4, 2013-08 ,pp. : 490-498

Informa Healthcare

Access to resources Recommend Favorite

Drospirenone and estradiol: a new option for the postmenopausal woman

By Archer D. F.  

Climacteric, Vol. 10, Iss. 1, 2007-01 ,pp. : 3-10

Informa Healthcare

Access to resources Recommend Favorite

Plasma leptin in postmenopausal women with coronary artery disease: effect of transdermal 17β-estradiol and intermittent medroxyprogesterone acetate

By Os I.   Os A.   Abdelnoor M.   Larsen A.   Birkeland K.   Westheim A.  

Climacteric, Vol. 6, Iss. 3, 2003-09 ,pp. : 204-210

Informa Healthcare

Access to resources Recommend Favorite

Low-dose oral combination of 17β-estradiol and norethisterone acetate in postmenopausal women decreases factor VII, fibrinogen, antithrombin and plasminogen activator inhibitor-1

By Borgfeldt C.   Li C.   Samsioe G.  

Climacteric, Vol. 7, Iss. 1, 2004-01 ,pp. : 78-85

Informa Healthcare

Access to resources Recommend Favorite